基因组编辑药物产品：欧洲药品管理局的观点。 - Suppr

Suppr

超能文献

Genome-editing medicinal products: the EMA perspective.

作者信息

Tavridou Anna, Rogers Dolça, Farinelli Giada, Gravanis Iordanis, Jekerle Veronika

出版信息

Nat Rev Drug Discov. 2024 Apr;23(4):242-243. doi: 10.1038/d41573-024-00050-2.

DOI:10.1038/d41573-024-00050-2

PMID:38491159

Abstract

摘要

相似文献

Genome-editing medicinal products: the EMA perspective.

Nat Rev Drug Discov. 2024 Apr;23(4):242-243. doi: 10.1038/d41573-024-00050-2.

CRISPR/Cas genome editing to optimize pharmacologically active plant natural products.

Pharmacol Res. 2021 Feb;164:105359. doi: 10.1016/j.phrs.2020.105359. Epub 2020 Dec 4.

CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.

Recent Pat Anticancer Drug Discov. 2021;16(4):460-468. doi: 10.2174/1574892816666210706155602.

Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.

Plant Biotechnol J. 2020 Aug;18(8):1651-1669. doi: 10.1111/pbi.13383. Epub 2020 Apr 30.

[Prospecting application of CRISPR/Cas9 genome editing technology in research of medicinal plants].

Zhongguo Zhong Yao Za Zhi. 2016 Aug;41(16):2953-2957. doi: 10.4268/cjcmm20161602.

CRISPR-Cas systems: ushering in the new genome editing era.

Bioengineered. 2018;9(1):214-221. doi: 10.1080/21655979.2018.1470720.

Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.

Genes Genomics. 2019 Aug;41(8):871-877. doi: 10.1007/s13258-019-00830-w. Epub 2019 May 22.

Multiplex genome editing of microorganisms using CRISPR-Cas.

FEMS Microbiol Lett. 2019 Apr 1;366(8). doi: 10.1093/femsle/fnz086.

Application of the CRISPR/Cas system for genome editing in microalgae.

Appl Microbiol Biotechnol. 2019 Apr;103(8):3239-3248. doi: 10.1007/s00253-019-09726-x. Epub 2019 Mar 15.

[Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].

Yi Chuan. 2020 Jun 20;42(6):556-564. doi: 10.16288/j.yczz.20-017.

引用本文的文献

The hidden risks of CRISPR/Cas: structural variations and genome integrity.

Nat Commun. 2025 Aug 5;16(1):7208. doi: 10.1038/s41467-025-62606-z.

CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer's Disease.

Antioxidants (Basel). 2025 Jun 25;14(7):781. doi: 10.3390/antiox14070781.

The impact of the three major human genome editing reports on the governance landscape.

J Community Genet. 2025 Oct;16(5):503-512. doi: 10.1007/s12687-025-00809-z. Epub 2025 Jun 16.

Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications.

Nanomaterials (Basel). 2025 Apr 2;15(7):540. doi: 10.3390/nano15070540.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Genome-editing medicinal products: the EMA perspective.

Nat Rev Drug Discov. 2024 Apr;23(4):242-243. doi: 10.1038/d41573-024-00050-2.

CRISPR/Cas genome editing to optimize pharmacologically active plant natural products.

Pharmacol Res. 2021 Feb;164:105359. doi: 10.1016/j.phrs.2020.105359. Epub 2020 Dec 4.

CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.

Recent Pat Anticancer Drug Discov. 2021;16(4):460-468. doi: 10.2174/1574892816666210706155602.

Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.

Plant Biotechnol J. 2020 Aug;18(8):1651-1669. doi: 10.1111/pbi.13383. Epub 2020 Apr 30.

[Prospecting application of CRISPR/Cas9 genome editing technology in research of medicinal plants].

Zhongguo Zhong Yao Za Zhi. 2016 Aug;41(16):2953-2957. doi: 10.4268/cjcmm20161602.

CRISPR-Cas systems: ushering in the new genome editing era.

Bioengineered. 2018;9(1):214-221. doi: 10.1080/21655979.2018.1470720.

Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.

Genes Genomics. 2019 Aug;41(8):871-877. doi: 10.1007/s13258-019-00830-w. Epub 2019 May 22.

Multiplex genome editing of microorganisms using CRISPR-Cas.

FEMS Microbiol Lett. 2019 Apr 1;366(8). doi: 10.1093/femsle/fnz086.

Application of the CRISPR/Cas system for genome editing in microalgae.

Appl Microbiol Biotechnol. 2019 Apr;103(8):3239-3248. doi: 10.1007/s00253-019-09726-x. Epub 2019 Mar 15.

[Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].

Yi Chuan. 2020 Jun 20;42(6):556-564. doi: 10.16288/j.yczz.20-017.

引用本文的文献

The hidden risks of CRISPR/Cas: structural variations and genome integrity.

Nat Commun. 2025 Aug 5;16(1):7208. doi: 10.1038/s41467-025-62606-z.

CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer's Disease.

Antioxidants (Basel). 2025 Jun 25;14(7):781. doi: 10.3390/antiox14070781.

The impact of the three major human genome editing reports on the governance landscape.

J Community Genet. 2025 Oct;16(5):503-512. doi: 10.1007/s12687-025-00809-z. Epub 2025 Jun 16.

Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications.

Nanomaterials (Basel). 2025 Apr 2;15(7):540. doi: 10.3390/nano15070540.